ENvue Medical, Inc.

NasdaqCM:FEED Stock Report

Market Cap: US$5.1m

ENvue Medical Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for ENvue Medical.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth16.2%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Analysis Article • Dec 09

Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

Shareholders may be wondering what CEO Brian Murphy plans to do to improve the less than great performance at...
Seeking Alpha • Oct 19

NanoVibronix receives extension to satisfy Nasdaq bid price requirement

NanoVibronix (NASDAQ:NAOV) receives extension to satisfy Nasdaq bid price requirement subject to the company’s satisfaction of certain conditions, including the provision of an update to the Panel on December 15, 2022. The Panel has the authority to grant the company an extension through February 23, 2023. The company will seek shareholder approval for the implementation of a reverse stock split if necessary and at the Board’s discretion to regain compliance with Nasdaq’s price requirement.
Seeking Alpha • Sep 23

NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract

NanoVibronix (NASDAQ:NAOV) said on Friday its UroShield had been approved to be sold in the UK by the NHS Supply Chain through a new contract. (NAOV) has risen ~27% before the bell. NHS Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organizations across England and Wales. The new contract will begin in October and will merge with the existing Urology and Stoma framework contract in February 2024 with optional extension periods. UroShield is a disposable ultrasound device designed to reduce the risk of catheter-associated urinary tract infection (CAUTI) by reducing bacterial colonization and biofilm formation on indwelling urinary catheters.
Analysis Article • Jul 08

Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Mar 22

Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Dec 01

Is NanoVibronix (NASDAQ:NAOV) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Sep 01

NanoVibronix: Portable Ultrasonic Therapeutic Devices

NanoVibronix develops and produces proprietary portable ultrasonic therapeutic devices. The company’s UroShield and PainShield Plus devices have been granted approval and reimbursement from the Federal Supply Schedule. The company recently launched an over-the-counter (OTC) derivative of one of its prescription products.
Analysis Article • Aug 17

NanoVibronix (NASDAQ:NAOV) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, NanoVibronix...

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ENvue Medical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

NasdaqCM:FEED - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20262-38-12-12N/A
12/31/20253-17-9-9N/A
9/30/20253-5-7-7N/A
6/30/20252-5-6-6N/A
3/31/20253-5-3-3N/A
12/31/20243-4-3-3N/A
9/30/20243-3-2-2N/A
6/30/20243-3-2-2N/A
3/31/20243-3-3-3N/A
12/31/20232-4-4-4N/A
9/30/20231-5-4-4N/A
6/30/20231-5-6-6N/A
3/31/20231-5-6-6N/A
12/31/20221-5-7-7N/A
9/30/20222-6-7-7N/A
6/30/20222-12-5-5N/A
3/31/20222-10-5-5N/A
12/31/20212-14-4-4N/A
9/30/20211-13-5-5N/A
6/30/20211-7-5-5N/A
3/31/20211-8-3-3N/A
12/31/20201-4-3-3N/A
9/30/20201-5-3-3N/A
6/30/20201-4-4-4N/A
3/31/20201-4-4-4N/A
12/31/20191-6N/A-4N/A
9/30/20190-6N/A-4N/A
6/30/20190-6N/A-3N/A
3/31/20190-6N/A-4N/A
12/31/20180-4N/A-4N/A
9/30/20180-5N/A-3N/A
6/30/20180-5N/A-3N/A
3/31/20180-6N/A-3N/A
12/31/20170-6N/A-2N/A
9/30/20170-5N/A-2N/A
6/30/20170-4N/A-2N/A
3/31/20170-3N/A-2N/A
12/31/20160-3N/A-2N/A
9/30/20160-2N/A-1N/A
6/30/20160-3N/A-1N/A
3/31/20160-3N/A-2N/A
12/31/20150-3N/A-1N/A
9/30/20150-3N/A-1N/A
6/30/20150-3N/A-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if FEED's forecast earnings growth is above the savings rate (3.5%).

Earnings vs Market: Insufficient data to determine if FEED's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if FEED's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if FEED's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if FEED's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if FEED's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/15 10:05
End of Day Share Price 2026/06/15 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ENvue Medical, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.